Markt geöffnet· · GBp · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
Financing co-led by Heal Capital and Ananda Impact Ventures will advance the Aitios® platform and ongoing validation of lead program to identify preeclampsia risk in a pregnancy’s first trimesterDr. Gordon Sanghera CBE FRS, co-founder and former CEO of Oxford Nanopore Technologies, joins Aitiologic’s advisory board and participates in the round as an investorDr. Rebecca Ertl, obstetrician-gynecologist and founder of a leading prenatal diagnostics center, appointed Chief Medical Officer VIENNA, S
The global transcriptome sequencing market is projected to reach $11.8 billion by 2035, growing at a 7.3% CAGR from 2025 to 2035. Growth is driven by falling sequencing costs, precision medicine, drug discovery, biomarker development, single-cell and spatial transcriptomics, long-read RNA sequencing, and AI-powered analytics. Consumables, bulk RNA-seq, drug discovery applications, and pharmaceutical and biotechnology companies led the market in 2025. North America held the largest regional share
Oxford Nanopore Technologies (LON:ONT) reported first-half revenue growth below its expectations as declines in China, the Middle East and delayed orders in the Americas weighed on performance, while gross-margin expansion and lower operating expenses narrowed its adjusted EBITDA loss. Revenue for
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.